Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis

Liver International

Volumn 25, Issue 3, 2005, Pages 657-666

  Heller, Jörg ^a   Trebicka, Jonel ^a   Shiozawa, Thomas ^a   Schepke, Michael ^a   Neef, Markus ^a   Hennenberg, Martin ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Angiotensin; Cirrhosis; Losartan; Portal hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; LOSARTAN; METHOXAMINE; NORADRENALIN; SODIUM;

ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; ATTENUATION; BILIARY CIRRHOSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; HYPOTHESIS; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MYOGRAPHY; NATRIURESIS; NONHUMAN; NORADRENALIN BLOOD LEVEL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; SMOOTH MUSCLE CONTRACTILITY; SODIUM EXCRETION; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC ALPHA-AGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; KIDNEY FAILURE; LIVER CIRCULATION; LIVER CIRRHOSIS, BILIARY; LOSARTAN; MALE; METHOXAMINE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, ALPHA-1; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE; VASODILATION;

EID: 20844436155     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01053.x     Document Type: Article

References (31)

1. Murray J F, Dawson A M, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-67.
2. Nicolls K M, Shapiro M D, Van Putten Y J, et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis: association with increased secretion rates, normal clearance rates and suppressibility by central volume expansion. Circ Res 1985; 56: 457-61.
3. Hadoke P W F, Hayes P C. In vitro evidence for vascular hyporesponsiveness in clinical and experimental cirrhosis. Pharmacol Ther 1997; 75: 51-68.
4. Schepke M, Heller J, Paschke S, et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology 2001; 34: 884-8.
5. Heller J, Schepke M, Gehnen N, et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999; 116: 387-93.
6. Michielsen P P, Boeckxstaens G E, Sys S U, et al. The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. J Hepatol 1995; 23: 341-47.
7. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus pro-pranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
8. Schneider A W, Kalk J F, Klein C P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
9. Schepke M, Werner E, Biecker E, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-95.
10. Heller J, Shiozawa T, Trebicka J, et al. Acute hemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003; 33: 1006-12.
11. Yang Y Y, Lin H C, Huang Y T, et al. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J Hepatol 2002; 36: 600-6.
12. Crespo M J. Interaction between AT1 and alpha 1-adrenergic receptors in cardiomyopathic hamsters. J Card Fail 2000; 6: 257-63.
13. Lee S S, Giroud C, Braillon A, et al. Hemodynamic characterization of chronic bile duct-ligated rats: effects of pentobarbital sodium. Am J Physiol 1986; 251: G176-80.
14. Kountouras J, Billing B H, Scheuer P J. Prolonged bile duct obstruction: a new model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
15. Strawn W B, Gallagher P E, Tallant E A, et al. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen)27 rats. J Cardiovasc Pharmacol 1999; 33: 341-55.
16. Seyde W C, Longnecker D E. Anesthetic influence on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology 1984; 61: 686-98.
17. Van de Casteele M, Sägesser H, Zimmermann H, et al. Characterization of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther 2001; 90: 35-43.
18. Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000; 32: 43-50.
19. Hakkinen J P, Miller M W, Smith A H, et al. Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res 1995; 29: 74-9.
20. Geraghty J G, Angerson W J, Carter D C. Portal venous pressure and portosystemic shunting in experimental portal hypertension. Am J Physiol 1989; 257: G52-7.
21. Heller J, Sogni P, Tazi K A, et al. Abnormal regulation of aortic NOS2 and NOS3 activity and expression from portal vein-stenosed rats after lipopolysaccharide administration. Hepatology 1999; 30: 698-704.
22. Weicker H, Feraudi M, Hagele H, et al. Electrochemical detection of catecholamines in urine and plasma after separation with HPLC. Clin Chim Acta 1984; 4: 17-25.
23. Li Y, Song D, Zhang Y, et al. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. Gut 2003; 52: 293-9.
24. Jonassen T E, Christensen S, Sorensen A M, et al. Effect of chronic octreotide treatment on renal changes during cirrhosis in rats. Hepatology 1999; 29: 1387-95.
25. Girgrah N, Liu P, Collier J, et al. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000; 46: 114-20.
26. Bautista R, Manning R, Martinez F, et al. Angiotensin II-dependent increased expression of Na+-glucose cotransportaer in hypertension. Am J Physiol Renal Physiol 2004; 286: F127-33.
27. Bayorh M A, Ganafa A A, Socci R R, et al. Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. Am J Hypertension 2003; 16: 387-92.
28. Croquet V, Moal F, Veal N, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002; 37: 773-80.
29. Schnabel P, Nohr T, Nickenig G, et al. α-Adrenergic signal transduction in renin transgenic rats. Hypertension 1997; 30: 1356-61.
30. Ye S, Zhong H, Duong V N, et al. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002; 39: 1001-6.
31. Treeck B, Roald A B, Tenstad O, Aukland K. Effect of exogenous and endogenous angiotensin on intrarenal distribution of glomerular filtration rate in rats. J Physiol 2002; 541: 1049-57.